



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





KRAS Mutation Analysis

Alternative Name

KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation)

Methodology

Molecular

Test Description

Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing is available separately or in combination with BRAF, HRAS and NRAS in the [RAS/RAF Panel](#).

KRAS testing in non-small cell lung cancer may provide prognostic information, predict poor response to EGFR tyrosine kinase inhibitors, and inform on possible response to targeted therapy such as sotorasib. Please see also [KRAS \(G12C\) Mutation Analysis for NSCLC](#), part of a sponsored testing program for stage IV NSCLC patients.

Clinical Significance

Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing in non-small cell lung cancer may provide prognostic information and predict poor response to EGFR tyrosine kinase inhibitors.

Specimen Requirements

- **FFPE solid tumor tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
- **Fine needle aspirate (FNA):** FFPE cell blocks are acceptable. Requisition must note specimen is FNA. Fresh cells and smears are not acceptable.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

81275, 81276

Medicare MoIDX CPT Code(s)*

81479

New York Approved

Yes

Level of Service

Global

Turnaround Time

7 days

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 042924